Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
OREXO AB SP/ADR (ORXOY)
NASDAQ:AMEX Investor Relations:
orexo.com/en/investors
Company Research
Source: PR Newswire
The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine platform.The AmorphOX technology has the potential to improve the stability and efficacy of Abera's vaccine candidates.UPPSALA, Sweden, Dec. 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), continues to develop its innovative powder-based drug delivery technology AmorphOX to improve the properties of new or existing drugs. The aim is to develop formulations that help to significantly stabilize the active ingredient and enable alternative and more effective routes of administration. AmorphOX-based formulations can be used for a wide range of active ingredients, from small molecules and peptides to larger biomolecules such as vaccines.As a next strategic step to leverage the scalability of AmorphOX, Orexo has entered into
Show less
Read more
Impact Snapshot
Event Time:
ORXOY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORXOY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORXOY alerts
High impacting OREXO AB SP/ADR news events
Weekly update
A roundup of the hottest topics
ORXOY
News
- Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology [Yahoo! Finance]Yahoo! Finance
- Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technologyPR Newswire
- Orexo initiates new study of OX640 in participants with allergic rhinitis [Yahoo! Finance]Yahoo! Finance
- Orexo initiates new study of OX640 in participants with allergic rhinitisPR Newswire
- Orexo initiates new study of OX640 in participants with allergic rhinitisPR Newswire